Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Finch Therapeutics Group, Inc.FNCH-1.370.001.021.78-67.28%-17.39%70.65$10.98$8.90828$12.05

Detail of Finch Therapeutics Group, Inc.

 
CEO
Mr. Matthew P. Blischak J.D.
Employees
1
Industry
Biotechnology
Sector
Healthcare
Market cap
$19M

Company details

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Finch Therapeutics Group, Inc.
FNCH • XNGS • US
$12.05
+9.50 (372.55%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$8.82
Margin profit
0.00%
52 week low
$0.8801
52 week high
$13.69
50-day simple moving average
$0.00
200-day simple moving average
$10.98
Percent held by insiders
53.46%
Percent held by institutions
3.31%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
FNCH +357.65%
eps change
FNCH 0.00%